Find investors
← Back to all investors
Brendan Houlihan
ResearchedAngel Investors

Brendan Houlihan

Angel InvestorsSeed Round
Pitch Brendan

Get their honest, personalized take on your startup.

Sign in to pitch Brendan

At a glance

Full Name
Brendan Houlihan
Title
Managing Director
Firm
Salem Partners
Firm Type
Independent boutique investment bank, merchant bank, valuation advisory practice, and wealth management firm
Investment Stage
Private placements and merchant-banking co-investments across growth companies; Salem has disclosed recent seed, Series B, convertible-note, and growth-investment activity, but no public source verifies Houlihan personally as an angel investor
Target Company Profile
Companies needing valuation opinions, fairness opinions, M&A advisory, restructuring advice, debt or equity capital raising, litigation/dispute valuation support, or valuation of IP, private funds, complex securities, and structured finance assets
Sector Focus
Valuation services across industries; technology, media, and entertainment
Geographic Focus
U.S., with Salem Partners headquartered in Los Angeles
Location
Los Angeles, California

Background

Brendan Houlihan is a Managing Director at Salem Partners, where he is responsible for the firm’s valuation practice across all industries. Salem Partners describes itself as an independent Los Angeles-based boutique investment bank and wealth management firm founded in 1997, with investment and merchant banking services spanning M&A advisory, strategic advisory, merchant banking, capital raising, valuations, and fairness opinions.

Houlihan has more than 20 years of experience in investment banking advisory and valuation. His transaction experience includes mergers and acquisitions, divestitures, financial restructuring, and debt and equity capital raising for clients in the technology, media, and entertainment industries.

His valuation work includes fairness and other financial opinions; valuation of intellectual property assets, businesses, private equity and hedge fund investments, goodwill and intangible assets, incentive compensation awards, estate and tax planning, derivatives, complex partnership and tax structures, and other structured finance assets. He also works as an expert witness in arbitration, litigation, dispute resolution, and related matters in the technology, media, and entertainment industry.

Before joining Salem Partners in 2003, Houlihan was an Associate in the Mergers and Acquisitions practice of Credit Suisse First Boston in San Francisco and an Analyst in the Technology Investment Banking practice at Warburg Dillon Read in San Francisco. He graduated from the University of California, Berkeley.

Investment Thesis & Focus

  • Public sources do not verify Houlihan as a standalone angel investor. The supportable profile is that he is an investment banker and valuation specialist at Salem Partners.
  • Salem Partners’ merchant banking model allows the firm to co-invest alongside advisory mandates; the firm says its principal investment track record spans operating companies and portfolios of media rights and intellectual property.
  • Salem Partners acts as exclusive agent in private placements of debt and equity securities for companies across industries, with stated expertise in capital structures, deal terms, governance, and valuation.
  • Houlihan’s likely relevance to founders is strongest where valuation, fairness opinions, complex capital structures, IP valuation, restructuring, or media/technology transaction work is central to the deal.
  • Salem’s valuation practice supports public and private companies across industries and geographies, including valuation work for M&A, debt or equity financings, internal corporate planning, market-value accounting, tax treatment, and fiduciary fairness opinions.

Notable Investments

  • Public sources reviewed did not identify Houlihan’s personal angel-investment portfolio.
  • Rightsline: Salem announced a $500 million strategic growth investment from Hg into Rightsline in 2026; Salem said it first partnered with Rightsline in 2017 and has participated as both investment banking advisor and investor.
  • GenrAb: Salem listed a 2025 financial-advisor role in GenrAb’s $5.6 million seed financing and a 2024 direct investment in GenrAb convertible notes.
  • OncoNano Medicine: Salem listed a 2025 financial-advisor role in OncoNano’s $12.7 million Series B preferred stock financing.
  • Renibus Therapeutics: Salem listed a 2023 direct investment in Renibus Therapeutics Series B preferred stock.
  • Form Bio: Salem listed a 2023 direct investment in Form Bio Series A preferred stock.
  • Gravitas Ventures / Shout! Studios: Salem was exclusive financial and investment banking advisor to Gravitas Ventures in its 2025 sale to Shout! Studios.
  • Oaktree Capital Management and Shout! Studios / FilmRise: Salem was exclusive advisor to Oaktree and Shout! Studios in connection with the 2025 acquisition and financing of FilmRise.
  • ValpakClipp: Salem advised ValpakClipp in securing a $140 million senior term loan and revolving credit facility in 2026.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.